Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2
- 7 February 2006
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (8) , 2109-2112
- https://doi.org/10.1016/j.bmcl.2006.01.066
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- HIV resistance and the effectiveness of combination antiretroviral treatmentDrug Discovery Today: Therapeutic Strategies, 2004
- New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infectionsCurrent Opinion in Pharmacology, 2004
- Inhibition of HIV-1 reverse transcription: basic principles of drug action and resistanceExpert Review of Anti-infective Therapy, 2004
- Update on HIV resistance and resistance testingMedicinal Research Reviews, 2003
- Virological Response in Multidrug-Experienced HIV-1-Infected Subjects Failing Highly Active Combination Regimens after Shifting from Lamivudine to DidanosineAntiviral Therapy, 2001
- HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapyAIDS, 2000
- Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptaseDrug Resistance Updates, 1999
- Resistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse TranscriptaseScience, 1991